Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (7681)	11/7/1998 3:30:00 PM
From: aknahow	Respond to of 17367

I will surprise you and say no I don't think an article like or identical to the O.C. register article would do much more than a small pop. Don't think it would move XOMA like ENMD or GERN. Why not? The article is similar to that in Discover. Great and important info about XOMA but it is a general article and XOMA only one of many mentioned. If and when Neuprex is used for Meningococcemia and someone impressed by the results writes a national article devoted only to Neuprex/XOMA and how it probably is or actually has proved itself as a promising tool for overcoming resistant bacteria, then I believe you have a ENMD/GERN situation but even better as the product will be on the market not just a distant dream. So if there is a run-up and the guys with VD, or at least the portfolio, short it, in their paper portfolio, (finally giving you your wish to include XOMA), they may end up disappointed because the story will have legs.